191 related articles for article (PubMed ID: 33999145)
21. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Chen L; Ouyang J; Wienand K; Bojarczuk K; Hao Y; Chapuy B; Neuberg D; Juszczynski P; Lawton LN; Rodig SJ; Monti S; Shipp MA
Haematologica; 2020 May; 105(5):1361-1368. PubMed ID: 31471373
[TBL] [Abstract][Full Text] [Related]
22. FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.
Sewastianik T; Szydlowski M; Jablonska E; Bialopiotrowicz E; Kiliszek P; Gorniak P; Polak A; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Kaminski TS; Markowicz S; Nowak E; Grygorowicz MA; Warzocha K; Juszczynski P
Oncogene; 2016 Nov; 35(46):5989-6000. PubMed ID: 27132507
[TBL] [Abstract][Full Text] [Related]
23. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
Monti S; Savage KJ; Kutok JL; Feuerhake F; Kurtin P; Mihm M; Wu B; Pasqualucci L; Neuberg D; Aguiar RC; Dal Cin P; Ladd C; Pinkus GS; Salles G; Harris NL; Dalla-Favera R; Habermann TM; Aster JC; Golub TR; Shipp MA
Blood; 2005 Mar; 105(5):1851-61. PubMed ID: 15550490
[TBL] [Abstract][Full Text] [Related]
25. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
Fernández-Rodríguez C; Salar A; Navarro A; Gimeno E; Pairet S; Camacho L; Ferraro M; Serrano S; Besses C; Bellosillo B; Sanchez-Gonzalez B
Leuk Lymphoma; 2016; 57(3):692-9. PubMed ID: 26084206
[TBL] [Abstract][Full Text] [Related]
27. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
30. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
[TBL] [Abstract][Full Text] [Related]
31. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
32. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
[TBL] [Abstract][Full Text] [Related]
33. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
34. SIRT1 and HSP90α feed-forward circuit safeguards chromosome segregation integrity in diffuse large B cell lymphomas.
Białopiotrowicz-Data E; Noyszewska-Kania M; Jabłońska E; Sewastianik T; Komar D; Dębek S; Garbicz F; Wojtas M; Szydłowski M; Polak A; Górniak P; Juszczyński P
Cell Death Dis; 2023 Oct; 14(10):667. PubMed ID: 37816710
[TBL] [Abstract][Full Text] [Related]
35. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
[TBL] [Abstract][Full Text] [Related]
36. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
37. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Mensah AA; Kwee I; Gaudio E; Rinaldi A; Ponzoni M; Cascione L; Fossati G; Stathis A; Zucca E; Caprini G; Bertoni F
Oncotarget; 2015 Mar; 6(7):5059-71. PubMed ID: 25671298
[TBL] [Abstract][Full Text] [Related]
38. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
39. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
40. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.
Caro P; Kishan AU; Norberg E; Stanley IA; Chapuy B; Ficarro SB; Polak K; Tondera D; Gounarides J; Yin H; Zhou F; Green MR; Chen L; Monti S; Marto JA; Shipp MA; Danial NN
Cancer Cell; 2012 Oct; 22(4):547-60. PubMed ID: 23079663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
